Dake Benjamin T. - 08 Sep 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
08 Sep 2022
Net transactions value
-$124,158
Form type
4
Filing time
12 Sep 2022, 17:30:09 UTC
Previous filing
08 Sep 2022
Next filing
14 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $5,429 +3,120 $1.74* 3,120 08 Sep 2022 Direct F1
transaction AVTE Common Stock Sale $45,193 -2,491 -80% $18.14 629 08 Sep 2022 Direct F1, F2
transaction AVTE Common Stock Sale $11,588 -629 -100% $18.42 0 08 Sep 2022 Direct F1, F3
transaction AVTE Common Stock Options Exercise $449 +258 $1.74* 258 09 Sep 2022 Direct F1
transaction AVTE Common Stock Options Exercise $9,549 +4,462 +1729% $2.14* 4,720 09 Sep 2022 Direct F1
transaction AVTE Common Stock Sale $79,540 -4,544 -96% $17.50 176 09 Sep 2022 Direct F1, F4
transaction AVTE Common Stock Sale $3,262 -176 -100% $18.54 0 09 Sep 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -648 -4.2% $0.000000 14,746 08 Sep 2022 Common Stock 648 $1.74 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -2,472 -6.7% $0.000000 34,656 08 Sep 2022 Common Stock 2,472 $1.74 Direct F1, F7
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -258 -1.7% $0.000000 14,488 09 Sep 2022 Common Stock 258 $1.74 Direct F1, F6
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -4,462 -9.1% $0.000000 44,420 09 Sep 2022 Common Stock 4,462 $2.14 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.39 to $18.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.40 to $18.505, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.06 to $18.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.07 to $18.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F7 A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F8 A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with shares vesting in 48 substantially equal monthly installments.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary